MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 15,027 shares, a decrease of 42.6% from the November 30th total of 26,198 shares. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short. Currently, 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is presently 0.1 days.MDxHealth Trading Down 1.7%NASDAQ:MDXH traded down $0.06 on Friday, reaching $3.41. The company's stock had a trading volume of 42,254 shares, compared to its average volume of 110,342. The stock has a 50 day moving average price of $3.84 and a 200 day moving average price of $3.37. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33. The company has a quick ratio of 1.02, a current ratio of 1.14 and a debt-to-equity ratio of 13.81. The firm has a market cap of $161.26 million, a price-to-earnings ratio of -5.33 and a beta of 1.59. MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. The company had revenue of $27.43 million during the quarter, compared to analysts' expectations of $24.11 million. On average, equities analysts anticipate that MDxHealth will post -1.15 EPS for the current fiscal year. Institutional Trading of MDxHealthLarge investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new stake in MDxHealth during the 3rd quarter worth about $48,000. Lido Advisors LLC acquired a new position in MDxHealth during the third quarter worth approximately $48,000. Citadel Advisors LLC raised its position in MDxHealth by 30.6% in the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company's stock valued at $228,000 after purchasing an additional 11,456 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth during the third quarter worth about $53,000. Finally, Bank of America Corp DE increased its position in MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company's stock valued at $70,000 after acquiring an additional 14,769 shares during the period. Wall Street Analysts Forecast GrowthA number of equities analysts have recently issued reports on MDXH shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a report on Saturday, August 30th. Lake Street Capital raised their target price on MDxHealth from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. BTIG Research reaffirmed a "buy" rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, TD Cowen raised their target price on MDxHealth from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, MDxHealth presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.75.View Our Latest Report on MDxHealthAbout MDxHealth (Get Free Report)MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management. MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.Read MoreFive stocks we like better than MDxHealthWall Street Stockpicker Names #1 Stock of 2026“$6.6 Trillion Of Customer Bank Deposits At Risk”Washington prepares for warA month before the crashDrop these 5 stocks now!This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in MDxHealth Right Now?Before you consider MDxHealth, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here